Ginkgo Bioworks. has been granted a patent for adeno-associated virus (AAV) vectors featuring modified capsid proteins. The patent includes methods for administering these vectors to cells or subjects in vivo, specifically highlighting a capsid protein with the amino acid sequence of SEQ ID NO: 2110. GlobalData’s report on Ginkgo Bioworks gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ginkgo Bioworks, was a key innovation area identified from patents. Ginkgo Bioworks's grant share as of July 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.
Modified aav capsid proteins and virus vectors for administration
The granted patent US12060390B2 outlines a novel adeno-associated virus (AAV) vector characterized by its specific capsid protein, which includes the amino acid sequence designated as SEQ ID NO: 2110. The claims detail the composition of the AAV vector, emphasizing its encapsidated nucleic acid, which may contain terminal repeat sequences and can include heterologous nucleic acid sequences. These sequences can encode various polypeptides, including therapeutic, immunogenic, or nuclease proteins such as Cas9 or Cpf1 nucleases. Additionally, the encapsidated nucleic acid may also encode untranslated RNAs, such as guide RNAs or interfering RNAs.
The patent further describes a pharmaceutical composition that incorporates the AAV vector along with a pharmaceutically acceptable carrier, as well as methods for introducing nucleic acids into cells using the AAV vector. It also includes claims related to the production of the AAV vector through the culturing of specific cells containing the necessary nucleic acids for replication and encapsidation. Furthermore, the patent encompasses an expression vector that encodes the AAV capsid protein, providing a comprehensive framework for the development and application of AAV vectors in gene therapy and other biotechnological fields.
To know more about GlobalData’s detailed insights on Ginkgo Bioworks, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
